DRR168534
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.340
- WNT_BETA_CATENIN_SIGNALING+0.280
- TGF_BETA_SIGNALING+0.270
- OXIDATIVE_PHOSPHORYLATION+0.240
- MYC_TARGETS_V1+0.220
- ADIPOGENESIS+0.200
- MYC_TARGETS_V2+0.180
- ANDROGEN_RESPONSE+0.170
- FATTY_ACID_METABOLISM+0.170
- PEROXISOME+0.170
Top 10 suppressed
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.500
- IL6_JAK_STAT3_SIGNALING-0.350
- INTERFERON_GAMMA_RESPONSE-0.310
- ALLOGRAFT_REJECTION-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- INFLAMMATORY_RESPONSE-0.290
- TNFA_SIGNALING_VIA_NFKB-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
- PANCREAS_BETA_CELLS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168550 | — | — | 0.859 |
| 2 | R370 | — | — | 0.822 |
| 3 | SRR12202454 | — | — | 0.791 |
| 4 | SRR6013557 | — | cohortA1 | 0.789 |
| 5 | C3L-02961 | — | cohortA2 | 0.779 |
| 6 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.772 |
| 7 | X2ea5b654.8b53.4e39.8f1a.129a46474ae2 | — | cohortA1 | 0.759 |
| 8 | SRR8943006 | — | — | 0.758 |
| 9 | TCGA-B6-A0I8-01A-11R-A034-07 | — | B | 0.751 |
| 10 | TCGA-DK-A1AA-01A-11R-A13Y-07 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |